FluxMPS™ Dulbecco’s Modified Eagle Medium (DMEM), Low Glucose w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ Dulbecco’s Modified Eagle Medium (DMEM), Low Glucose w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ DCP-DMEML-QPBR1X is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid DMEM Low Glucose formulation engineered for microphysiological systems (MPS), organ-on-a-chip (OoC), and microfluidic tissue models. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• Quadruple-stage filtration train: 0.1 µm → 0.04 µm → 0.1 µm → 0.04 µm final polish, reaching a 0.04 µm cut-off for microfluidic channel safety
• Minimal DMEM Low Glucose base: only D-glucose (1000 mg/L) retained; L-glutamine, sodium pyruvate, sodium bicarbonate and phenol red are left to researcher definition
• Endotoxin release specification < 0.05 EU/mL (LAL, USP <85>), tested per manufacturing batch
• Bicarbonate-free and phenol red-free formulation — compatible with Agilent Seahorse XF real-time metabolic assays, which require both exclusions
• Ultrapure Type 1 water (18.2 MΩ·cm) used throughout formulation and processing
• Manufactured under an ISO 13485:2016 quality management system; final QC at Diagnocine, Totowa, NJ
• 29 verified components across 4 formulation categories, released per lot with full raw-material traceability
• Custom pH, salts, glucose concentration and buffer system available on request — contact support@diagnocine.com

Engineered where standard media fails

Conventional 0.22 µm–filtered media passes mycoplasma-sized particles, subvisible aggregates, and fine particulates that clog microfluidic channels and can interfere with sensor readouts. FluxMPS™ is processed through four sequential filtration stages to a 0.04 µm final cut-off to reduce this burden.

Quadruple-stage filtration system

1. 1

   0.1 µm Prefiltration I

   Removes large particulate, cell debris and protein aggregates; protects the first 0.04 µm cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass a standard 0.22 µm filter, including the size range occupied by mycoplasma (0.2–0.3 µm).

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm cartridge from load carried over the first pass.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill and finish in a validated ISO Class 5 (Class 100) environment.

Designed for next-generation cell models

FluxMPS™ DCP-DMEML-QPBR1X supports demanding platforms from single-channel microfluidic chips to multi-organ body-on-a-chip systems, and its bicarbonate-free, phenol red-free formulation extends this to real-time metabolic assay platforms.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant of this formulation is available on request for automated bioreactor perfusion and robotic liquid handlers.

• Total Particulate Exclusion: 0.01 µm filtration removes nanoparticulate aggregates beyond the reach of the standard 0.04 µm train
• Valve & Sensor Protection: Reduces micro-fouling risk on solenoid valves and inline optical sensors
• Extended Perfusion Stability: Supports consistent nutrient delivery over weeks-long culture

Inquiry Required: Contact support@diagnocine.com for the 0.01 µm MPS Grade variant of this formulation.

Analytical release specifications

Every lot released against the full specification matrix below. CoA available on request: support@diagnocine.com.

Full composition (mg/L)

29 verified components, organized under 4 formulation categories (Inorganic Salts, Amino Acids, Vitamins, Others) across 3 tabs, released per lot with CAS traceability.

Manufacturing & compliance

Every FluxMPS™ product is manufactured and released under a multi-layer quality system spanning raw materials, in-process controls, and final-product testing.

How DCP-DMEML-QPBR1X compares

FluxMPS™ DCP-DMEML-QPBR1X vs. conventional 0.22 µm–filtered DMEM Low Glucose formulations.

Comparison figures from published supplier specifications, accessed 2 September 2026. Suppliers that publish no numeric endotoxin specification are shown as “Not specified”.

Frequently asked questions

Common questions about FluxMPS™ DCP-DMEML-QPBR1X.

Supporting literature

Key peer-reviewed publications supporting ultra-filtered, Microfluidics Suitable media in organ-on-a-chip and microfluidic research.

1. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
3. Ham RG. Clonal growth of mammalian cells in a chemically defined, synthetic medium. Proc Natl Acad Sci USA. 1965;53:288–293. doi:10.1073/pnas.53.2.288
4. Novak R, et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020;4:407–420. doi:10.1038/s41551-019-0497-x
5. Jang KJ, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol. 2013;5:1119–1129. doi:10.1039/c3ib40049b
6. Schimek K, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588–3598. doi:10.1039/c3lc50217a
7. Luni C, et al. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13:446–452. doi:10.1038/nmeth.3832
8. Sung JH, et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip. 2013;13:1201–1212. doi:10.1039/c3lc41017j